Quinolinone pharmaceutical co-crystal, and preparation method, pharmaceutical composition and application thereof

Through the eutectics formed by aripiprazole and saturated fatty acids, the low water solubility and easy crystallization problems of aripiprazole are solved by using hydrogen bond self-assembly and the interaction of carboxyl and alkane chains, and the problem of high solubility is achieved and bioavailability, simplifying formulation processing.

CN118955369AActive Publication Date: 2024-11-15CHINA PHARM UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411003638.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-15
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

The low water solubility, ease of crystallization and instability of aripiprazole limits its application, and existing deep eutectic systems have challenges in formulation processing and bioavailability.

Method used

The eutectics formed by aripiprazole and saturated fatty acids of 10 to 16 carbons are self-assembled through hydrogen bonds on the amide group and piperazine ring, and hydrogen bonds between carboxyl and alkane chains are combined to form a stable eutectic structure. Improve solubility and bioavailability.

Benefits of technology

It significantly improves the solubility, dissolution rate and stability of aripiprazole, improves bioavailability, and simplifies the preparation process of the preparation, suitable for a variety of preparation forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_7
    Figure SMS_7
  • Figure SMS_58
    Figure SMS_58
  • Figure SMS_59
    Figure SMS_59
Patent Text Reader

Abstract

The invention discloses a quinolinone pharmaceutical co-crystal as well as a preparation method, a pharmaceutical composition and application thereof. The pharmaceutical co-crystal is a series of pharmaceutical co-crystals formed by aripiprazole and a fatty acid ligand, the physicochemical property and the drug release behavior of aripiprazole can be remarkably improved, and compared with a commercially available aripiprazole crystal form III, the pharmaceutical co-crystal is higher in solubility, faster in drug dissolution, more stable in a liquid state and better in bioavailability, and patent medicine and clinical application are facilitated. Meanwhile, the preparation method is convenient and economical, and industrial preparation is easy to realize.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a quinolinone drug co-crystal and a preparation method, a pharmaceutical composition and an application thereof, and in particular to a quinolinone drug co-crystal having excellent physical and chemical properties and capable of regulating drug release behavior and a preparation method, a pharmaceutical composition and an application thereof. Background Art

[0002] Aripiprazole is a quinolone atypical antipsychotic drug with good efficacy and few side effects. According to the BDDCS classification system, aripiprazole belongs to Class II drugs, and its solubility in water at 25°C is only 0.045 mg / L, which affects its absorption in the body. At the same time, aripiprazole tastes slightly bitter and is prone to crystallization in vivo and in vitro, forming aripiprazole monohydrate with poorer water solubility, which in turn affects the drug's metabolic kinetic behavior in the body and limits its further application.

[0003] Structural insights into novel therapeutic deep eutectic systems with capric acid using 1D, 2D NMR and DSC techniques with superior gut permeability (RSC Adv., 2024, 14, 14793-14806) discloses a deep eutectic system formed by aripiprazole and capric acid. Through nuclear magnetic hydrogen spectrum analysis, in the aripiprazole-decanoic acid deep eutectic system, the drug forms weak interaction forces with capric acid through the amide group and the nitrogen atom adjacent to the benzene ring on the piperazine ring. In terms of basic physicochemical properties, the aripiprazole-decanoic acid deep eutectic system has a lower melting point than a single-component substance, exists in liquid or slurry form at room temperature, and has a certain viscosity, which is not conducive to subsequent preparation processing, such as grinding, mixing, tableting, granulation, etc., and the preparation is relatively difficult. Summary of the invention

[0004] Purpose of the invention: The first purpose of the present invention is to provide a new quinolinone drug co-crystal, the second purpose is to provide a method for preparing the drug co-crystal, the third purpose is to provide a pharmaceutical composition containing the drug co-crystal, and the fourth purpose is to provide a pharmaceutical application of the drug co-crystal.

[0005] Technical solution: The quinolinone drug cocrystal of the present invention is formed by aripiprazole and a saturated fatty acid ligand with 10 to 16 carbon atoms; in the drug cocrystal structure, the amide groups of two aripiprazole molecules self-assemble through NH…O hydrogen bonds to form a The homodimer is extended by an OH...N hydrogen bond formed by a hydroxyl group on the carboxyl end of the saturated fatty acid molecule and a nitrogen atom on the piperazine ring in the aripiprazole molecule that is far away from the benzene ring.

[0006] Preferably, in the drug cocrystal structure, the CH...O hydrogen bond formed by the carbonyl group at the carboxyl end of the saturated fatty acid molecule and the alkane on the piperazine ring in the aripiprazole molecule and the CH...O hydrogen bond formed by the hydroxyl group at the carboxyl end of the saturated fatty acid molecule and the benzene ring in the aripiprazole molecule also participate in the construction of the aripiprazole cocrystal of the present invention.

[0007] More preferably, the amide groups of the two aripiprazole molecules are bonded by NH…O hydrogen bonds (bond length ) self-assembled The homodimer is a homodimer, wherein the dimer forms an OH...N hydrogen bond (bond length 10 ... ) extends, the CH…O hydrogen bond (bond length ) and the CH…O hydrogen bond (bond length ) participated in the construction of the aripiprazole cocrystal described in the present invention.

[0008] Preferably, the saturated fatty acid is selected from capric acid, lauric acid, myristic acid, and palmitic acid, wherein the molar ratio of aripiprazole to the saturated fatty acid is 1-2:1-2.

[0009] More preferably, the molar ratio of aripiprazole to saturated fatty acid is 1:1.

[0010] Drug cocrystal refers to a solid single-phase substance in which the active ingredient of a drug is connected to a ligand through weak interactions in a specific chemical ratio. This substance has no charge transfer and is not a solvate. Compared with other strategies for regulating the in vivo and in vitro properties of active ingredients of drugs, the drug cocrystal strategy can effectively regulate the basic physicochemical properties and in vivo and in vitro release behavior of drugs without affecting the pharmacodynamic activity. Fatty acids are one of the essential substances for organisms to maintain normal physiological activities and are widely present in nature. Due to their good biocompatibility and safety, they have been widely used in the design of multi-component drugs (drug cocrystals, salts).

[0011] The present invention aims at the deficiencies in the physicochemical properties (solubility, stability, medication compliance, etc.) and bioavailability of aripiprazole, adopts a drug co-crystal strategy, combines fatty acids with aripiprazole through non-covalent bonds, and improves the solubility, dissolution rate, stability and bioavailability of aripiprazole without changing the drug efficacy. Compared with the commercially available aripiprazole crystal form III, the aripiprazole-fatty acid co-crystal designed by the present invention can significantly improve solubility and bioavailability, accelerate intrinsic dissolution and improve stability. At the same time, the solubility, dissolution rate and solution stability show a significant correlation with the length of the fatty acid alkane chain. The shorter the alkane chain of the fatty acid and the drug co-crystal formed by aripiprazole, the higher the solubility and the faster the intrinsic dissolution rate; the longer the alkane chain of the fatty acid and the drug co-crystal formed by aripiprazole, the higher the solution stability in water.

[0012]

[0013] In addition, the aripiprazole-fatty acid drug co-crystal designed by the present invention exists in a solid form at room temperature, and its physical form is suitable for a variety of preparation processes, so it can be used for the development of different preparation forms; in particular, the improvement of liquid stability enables it to maintain an effective crystal form in liquid preparations. In addition, the drug and the ligand in the aripiprazole-fatty acid co-crystal are connected by weak interactions at a specific chemical dosage ratio, have a clear crystal structure, and have a more obvious correspondence with the solid-state physical and chemical properties, which has more advantages in quality evaluation and process control.

[0014] The aripiprazole-decanoic acid cocrystal of the present invention is a triclinic crystal system. Space group; unit cell parameters are α=81.285(4)°, β=82.440(5)°, γ=74.182(4)°.

[0015] In the above aripiprazole cocrystal structure, the amide groups of the two aripiprazole molecules are bonded together by NH…O hydrogen bonds (N3-H3…O2, ) self-assembled The further extension of the dimer is mainly through the OH…N(O3-H3B…N2, ) hydrogen bond. In addition, the carbonyl group at the carboxyl end of decanoic acid forms a CH…O(C9-H9A…O4, ) hydrogen bond and the CH…O(C3-H3A…O3, formed by the hydroxyl group at the carboxyl end of decanoic acid and the benzene ring of aripiprazole )Hydrogen bonds are also involved in the construction of aripiprazole-decanoic acid cocrystal.

[0016] Preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-decanoic acid cocrystal has characteristic diffraction peaks at 4.14°, 8.32°, 16.72°, 19.74°, and 22.24°.

[0017] Further preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-decanoic acid cocrystal has characteristic diffraction peaks at 4.14°, 8.32°, 16.72°, 17.10°, 19.74°, 21.64°, 22.24°, 23.28°, and 25.16°.

[0018] More preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-decanoic acid cocrystal has characteristic diffraction peaks at 4.14°, 8.32°, 9.60°, 11.60°, 12.78°, 13.96°, 16.72°, 17.10°, 18.14°, 18.72°, 19.26°, 19.74°, 20.94°, 21.64°, 22.24°, 23.28°, 23.68°, 24.00°, 24.46°, 24.84°, 25.16°, and 26.24°.

[0019] Preferably, the aripiprazole-decanoic acid cocrystal has a characteristic melting peak at 75.3±0.5°C.

[0020] The aripiprazole-lauric acid cocrystal of the present invention is a triclinic crystal system. Space group; unit cell parameters are α=91.364(2)°, β=98.872(2)°, γ=106.0730(10)°.

[0021] In the above aripiprazole cocrystal structure, the amide groups of the two aripiprazole molecules are bonded together by NH…O hydrogen bonds (N3-H3…O2, ) self-assembled The further extension of the dimer is mainly through the OH…N(O4-H4A…N2, ) hydrogen bond. In addition, the carbonyl group at the carboxyl end of lauric acid forms a CH…O(C9-H9A…O3, ) hydrogen bond and the CH…O(C3-H3A…O4, )Hydrogen bonds are also involved in the construction of aripiprazole-lauric acid cocrystal.

[0022] Preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-lauric acid cocrystal has characteristic diffraction peaks at 3.90°, 7.82°, 9.64°, 15.7°, 18.14°, 20.76°, 21.54°, 23.62°, and 24.44°.

[0023] Further preferably, expressed as a diffraction angle 2θ±0.2°, the aripiprazole-lauric acid cocrystal has characteristic diffraction peaks at 3.90°, 7.82°, 9.64°, 15.70°, 17.14°, 18.14°, 18.36°, 18.66°, 20.76°, 21.54°, 23.62°, 24.44°, and 28.24°.

[0024] More preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-lauric acid cocrystal has characteristic diffraction peaks at 3.90°, 7.82°, 9.64°, 11.06°, 13.00°, 13.40°, 15.70°, 17.14°, 18.14°, 18.36°, 18.66°, 19.18°, 19.38°, 20.76°, 21.24°, 21.54°, 22.20°, 23.62°, 24.44°, 27.60°, and 28.24°.

[0025] Preferably, the aripiprazole-lauric acid cocrystal has a characteristic melting peak at 80.5±0.4°C.

[0026] The aripiprazole-myristic acid cocrystal of the present invention is a triclinic system. Space group; unit cell parameters are α=95.2340(10)°, β=93.7410(10)°, γ=106.2470(10)°.

[0027] In the above aripiprazole cocrystal structure, the amide groups of the two aripiprazole molecules are bonded together by NH…O hydrogen bonds (N3-H3…O2, ) self-assembled The further extension of the dimer is mainly through the OH…N(O3-H3B…N2, ) hydrogen bond. In addition, the carbonyl group at the carboxyl end of myristic acid forms a CH…O(C9-H9A…O4, ) hydrogen bond and the CH…O(C3-H3A…O3, )Hydrogen bonds are also involved in the construction of aripiprazole-myristic acid cocrystal.

[0028] Preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-myristic acid cocrystal has characteristic diffraction peaks at 3.72°, 7.43°, 14.90°, 17.18°, 18.22°, 18.67°, 23.10°, 26.52°, and 27.82°.

[0029] Further preferably, expressed as a diffraction angle 2θ±0.2°, the aripiprazole-myristic acid cocrystal has characteristic diffraction peaks at 3.72°, 7.43°, 14.90°, 17.18°, 18.22°, 18.67°, 19.54°, 20.12°, 21.20°, 21.7°, 22.45°, 23.10°, 23.28°, 26.52°, and 27.82°.

[0030] More preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-myristic acid cocrystal has characteristic diffraction peaks at 3.72°, 7.43°, 9.78°, 10.54°, 11.18°, 12.76°, 12.96°, 13.18°, 14.90°, 17.18°, 18.22°, 18.67°, 19.54°, 20.12°, 21.20°, 21.7°, 22.45°, 23.10°, 23.28°, 23.7°, 24.24°, 24.44°, 26.00°, 26.24°, 26.52°, and 27.82°.

[0031] Preferably, the aripiprazole-myristic acid cocrystal has a characteristic melting peak at 85.3±0.3°C.

[0032] The aripiprazole-palmitic acid eutectic of the present invention is a triclinic crystal system. Space group; unit cell parameters are α=70.367(2)°, β=80.901(2)°, γ=78.615(2)°.

[0033] In the above aripiprazole cocrystal structure, the amide groups of the two aripiprazole molecules are bonded together by NH…O hydrogen bonds (N6-H6…O5, N9-H9…O2, N3-H3…O10, ) self-assembled The further extension of the dimer is mainly through the OH…N(O4-H4A…N2, O8-H8…N5, O12-H12…N8, ) hydrogen bond. In addition, the carbonyl group at the carboxyl end of palmitic acid forms a CH…O(C10-H10C…O11, C88-H88A…O7, C48-H48A…O3, ) hydrogen bond and the CH…O(C3-H3A…O4, C22-H22A…O5, C42-H42…O8, C81-H81…O12, )Hydrogen bonds are also involved in the construction of aripiprazole-palmitic acid cocrystal.

[0034] Preferably, expressed as a diffraction angle of 2θ±0.2°, the aripiprazole-palmitic acid cocrystal has characteristic diffraction peaks at 3.56°, 7.02°, 14.10°, 17.18°, 17.70°, 18.28°, 21.14°, 21.58°, 21.78°, 24.20°, and 24.92°.

[0035] Further preferably, expressed as a diffraction angle 2θ±0.2°, the aripiprazole-palmitic acid cocrystal has characteristic diffraction peaks at 3.56°, 7.02°, 9.78°, 10.54°, 14.10°, 17.18°, 17.70°, 18.28°, 18.34°, 18.88°, 21.14°, 21.58°, 21.78°, 24.20°, and 24.92°.

[0036] More preferably, expressed as a diffraction angle 2θ±0.2°, the aripiprazole-palmitic acid cocrystal has characteristic diffraction peaks at 3.56°, 7.02°, 8.52°, 9.78°, 10.08°, 10.54°, 12.44°, 12.80°, 14.10°, 16.26°, 17.18°, 17.70°, 18.28°, 18.34°, 18.88°, 19.34°, 19.96°, 21.14°, 21.58°, 21.78°, 22.56°, 22.88°, 23.24°, 24.20°, 24.92°, 27.38°, and 28.38°.

[0037] Preferably, the aripiprazole-palmitic acid cocrystal has a characteristic melting peak at 87.1±0.3°C.

[0038] The method for preparing the aripiprazole cocrystal of the present invention is selected from any of the following methods:

[0039] Method 1: preparing a suspension of aripiprazole and fatty acid, stirring, and removing the solvent to obtain the co-crystal;

[0040] Method 2: dissolving aripiprazole and fatty acid, filtering, removing the solvent from the filtrate, and crystallizing to obtain the co-crystal;

[0041] Method 3: dissolving aripiprazole and fatty acid, then mixing with the mixture, and removing the solvent to obtain the co-crystal;

[0042] Method 4: heating aripiprazole and fatty acid until they are melted and cooling them to obtain the co-crystal;

[0043] Method 5: dissolving aripiprazole and fatty acid, cooling, and removing the solvent to obtain the co-crystal;

[0044] Method 6: Aripiprazole and fatty acid are mixed and ground to obtain the co-crystal.

[0045] Preferably, in method one, the molar ratio of aripiprazole to fatty acid is 1:2 to 2:1, more preferably 1:1; the solvent used is selected from one or more of methanol, ethanol, isopropanol, acetone, ethyl acetate, toluene, tetrahydrofuran, dichloromethane, chloroform, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, and N-methylpyrrolidone, more preferably acetonitrile; the mass volume ratio of aripiprazole to solvent is 1:5 to 1:20, more preferably 1:8 to 1:15; the stirring temperature is room temperature, and the method for removing the solvent is filtration.

[0046] Preferably, in method 2, the molar ratio of aripiprazole to fatty acid is 1:2 to 2:1, more preferably 1:1; the solvent used is selected from one or more of methanol, ethanol, isopropanol, acetone, ethyl acetate, toluene, tetrahydrofuran, dichloromethane, chloroform, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, and N-methylpyrrolidone, more preferably acetonitrile; the mass volume ratio of aripiprazole to solvent is 1:100 to 1:500, more preferably 1:150 to 1:350; the dissolution method is heating or ultrasonic dissolution, and the method for removing the solvent is normal pressure volatilization or reduced pressure evaporation.

[0047] Preferably, in method three, the molar ratio of aripiprazole to fatty acid is 1:2 to 2:1, more preferably 1:1; the solvent used is selected from one or more of methanol, ethanol, isopropanol, acetone, ethyl acetate, toluene, tetrahydrofuran, dichloromethane, chloroform, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, and N-methylpyrrolidone, more preferably acetone or dimethyl sulfoxide; the anti-solvent used is selected from one or more of water methanol, ethanol, isopropanol, acetone, ethyl acetate, toluene, tetrahydrofuran, dichloromethane, chloroform, and acetonitrile, more preferably water; the mass volume ratio of aripiprazole to solvent is 1:50 to 1:200, more preferably 1:80 to 1:120; the mixing temperature is 0 to 10°C, and the method for removing the solvent is filtration.

[0048] Preferably, in method 4, the molar ratio of aripiprazole to fatty acid is 1:2 to 2:1, more preferably 1:1; the heating and melting temperature is 120 to 150°C, more preferably 135 to 145°C, further preferably 135°C, 136°C, 137°C, 138°C, 139°C, 140°C, 141°C, 142°C, 143°C, 144°C, 145°C, and most preferably 140±5°C.

[0049] Preferably, in method five, the molar ratio of aripiprazole to fatty acid is 1:2 to 2:1, more preferably 1:1; the solvent used for dissolution is selected from one or more of methanol, ethanol, isopropanol, acetone, ethyl acetate, toluene, tetrahydrofuran, dichloromethane, chloroform, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, and N-methylpyrrolidone, more preferably acetone or dimethyl sulfoxide; the mass volume ratio of aripiprazole to solvent is 1:100 to 1:500, more preferably 1:150 to 1:350; the dissolution method is heating or ultrasonic dissolution-assisted, and the cooling method is natural cooling or programmed cooling.

[0050] Preferably, in method six, the molar ratio of aripiprazole to fatty acid is 1:2 to 2:1, more preferably 1:1; a solvent is added or not added during the grinding process, more preferably a solvent is added to assist the grinding, and the solvent is selected from one or more of methanol, ethanol, isopropanol, acetone, ethyl acetate, toluene, tetrahydrofuran, dichloromethane, chloroform, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, and N-methylpyrrolidone, more preferably acetonitrile or acetone; the mass volume ratio of the mixed solid to the solvent is 1:10 to 1:100, more preferably 1:20.

[0051] The pharmaceutical composition of the present invention uses the aripiprazole-fatty acid co-crystal of the present invention as an active ingredient.

[0052] Preferably, the aripiprazole-fatty acid cocrystal of the present invention can be added with a pharmaceutically acceptable carrier to prepare a common pharmaceutical preparation. The pharmaceutically acceptable carrier can be an excipient widely used in the field of drug production. Excipients are mainly used to provide a safe, stable and functional pharmaceutical composition, and can also provide a method to dissolve the active ingredient at a desired rate after the subject receives the administration, or promote the effective absorption of the active ingredient after the subject receives the composition. The pharmaceutical excipient can be an inert filler, or provide a certain function, such as stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient of the composition. The pharmaceutical excipient can include one or more of the following excipients: binders, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents, sweeteners, etc.

[0053] The pharmaceutical composition of the present invention can be prepared according to the disclosed content using any method known to those skilled in the art, such as conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding or lyophilizing processes.

[0054] The pharmaceutical composition of the present invention can be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid preparations), inhalation, ocular, rectal, topical or parenteral (infusion, injection, implantation, subcutaneous, intravenous, intraarterial, intramuscular) administration. The pharmaceutical composition of the present invention can also be a controlled release or sustained release dosage form (e.g., liposomes or microspheres). Examples of solid oral preparations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions. Examples of topical preparations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum preparations. Examples of preparations for parenteral administration include, but are not limited to, solutions for injection, dry powder preparations that can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic preparations; aerosols, such as nasal sprays or inhalers; liquid dosage forms suitable for parenteral administration; suppositories and lozenges.

[0055] The aripiprazole-fatty acid cocrystal or the pharmaceutical composition thereof of the present invention is used in the preparation of drugs for preventing and / or treating central nervous system diseases or diseases related to the central nervous system.

[0056] Preferably, the drug is a drug for preventing and / or treating schizophrenia, mania, bipolar disorder, mixed episode of bipolar disorder, depression, autism, autism-related hypersensitivity, Tourette syndrome, Alzheimer's disease, dementia, epilepsy, anxiety, tic disorder, irritability associated with childhood autism, Tourette syndrome, alcoholism, trichotillomania, dermatitis, autism spectrum disorder, tumor, emergence delirium, attention deficit disorder with hyperactivity, metabolic syndrome, postpartum depression, developmental disorder, opioid dependence, cocaine addiction, Asperger's syndrome, HIV infection, fragile X syndrome, post-traumatic stress disorder, and weight change caused by mental disorder.

[0057] Preferably, the subjects of use of the drug include adults, teenagers, and children.

[0058] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:

[0059] The aripiprazole-fatty acid series co-crystals designed by the present invention can significantly improve the physical and chemical properties of aripiprazole and regulate the release behavior of the drug. Compared with the commercially available aripiprazole crystal form III, the co-crystals have higher solubility, faster drug dissolution, greater stability in liquid state, and better bioavailability, which are beneficial to drug formulation and clinical application. At the same time, the preparation method is convenient and economical, and is easy to realize industrial preparation. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 The single crystal asymmetric unit structure diagram and molecular stacking diagram of the aripiprazole-decanoic acid co-crystal prepared in Example 5;

[0061] Figure 2 The single crystal asymmetric unit structure diagram of the aripiprazole-lauric acid co-crystal prepared in Example 6;

[0062] Figure 3 The single crystal asymmetric unit structure diagram of the aripiprazole-myristic acid co-crystal prepared in Example 7;

[0063] Figure 4 The single crystal asymmetric unit structure diagram of the aripiprazole-palmitic acid co-crystal prepared in Example 8;

[0064] Figure 5 Thermogravimetric analysis diagrams of aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and aripiprazole Form III prepared in Example 25;

[0065] Figure 6 The differential scanning calorimetry diagrams of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and the aripiprazole crystal form III prepared in Example 25;

[0066] Figure 7X-ray powder diffraction patterns of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and the aripiprazole crystal form III prepared in Example 25;

[0067] Figure 8 The powder dissolution diagrams of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and the aripiprazole crystal form III prepared in Example 25;

[0068] Fig. 9 The Raman images of the powder dissolution residues of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and the aripiprazole crystal form III prepared in Example 25;

[0069] Fig.10 The intrinsic dissolution time-concentration graphs of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and the aripiprazole crystal form III prepared in Example 25;

[0070] Fig.11 The intrinsic dissolution rate graphs of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and the aripiprazole crystal form III prepared in Example 25;

[0071] Fig.12 The Raman images of the intrinsic dissolution residues of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 and the aripiprazole crystal form III prepared in Example 25;

[0072] Fig.13 The stability of the aripiprazole-fatty acid co-crystals prepared in Examples 1 to 4 under accelerated test conditions (40° C. / 75% RH);

[0073] Fig.14 Pharmacokinetic curves of the aripiprazole-fatty acid co-crystals prepared in Examples 2 to 4 and the aripiprazole crystal form III prepared in Example 25. DETAILED DESCRIPTION

[0074] The technical solution of the present invention is further described below in conjunction with embodiments.

[0075] The instruments used for solid-state characterization of drug co-crystals in the present invention are as follows:

[0076] The instrument used for thermogravimetric analysis characterization was a TAQ500 thermogravimetric analyzer, and the method was to add 5-15 mg of sample into a platinum pan and heat it to 400° C. at a heating rate of 20° C. / min. The heating environment was a high-purity (99.99%) nitrogen atmosphere with a nitrogen flow rate of 40 mL / min.

[0077] The instrument model used for differential scanning calorimetry analysis is TAQ2000 differential scanning calorimeter, and the method is to weigh 3-5 mg of sample into a sealed aluminum crucible and heat it to 160° C. at a heating rate of 10° C. / min. The instrument is calibrated regularly with metallic indium, and the heating environment is a high-purity (99.99%) nitrogen atmosphere with a nitrogen flow rate of 50 mL / min.

[0078] The instrument used for powder X-ray diffraction characterization is a Japanese Rigaku SmartLab SE powder X-ray diffractometer; target: Cu-Kα ray Tube voltage: copper palladium 40 kV; current: 40 mA; 2θ range: 3-40°; scanning step: 0.02°; scanning rate: 10° / min.

[0079] The Raman spectrometer was Thermo Fisher Scientific DXR, with a laser wavelength of 780 nm, a magnification of 10×, an exposure time of 1 s, 30 acquisitions, and a laser power of 15 mW.

[0080] Example 1

[0081] Weigh 2.24 g of aripiprazole and 0.86 g of capric acid, mix them, add 10 mL of acetonitrile solution to make a suspension, stir at room temperature for 3 days, filter, and vacuum dry at 40°C for 48 h. Perform PXRD, DSC, and TGA characterization to confirm that aripiprazole-decanoic acid cocrystal (APZ-C10) is obtained.

[0082] Example 2

[0083] Weigh 2.24 g of aripiprazole and 1.00 g of lauric acid, mix, add 10 mL of acetonitrile solution to form a suspension, stir at room temperature for 3 days, filter, and vacuum dry at 40°C for 48 h. Perform PXRD, DSC, and TGA characterization to confirm that aripiprazole-lauric acid cocrystal (APZ-C12) is obtained.

[0084] Example 3

[0085] Weigh 2.24 g of aripiprazole and 1.14 g of myristic acid, mix, add 10 mL of acetonitrile solution to form a suspension, stir at room temperature for 3 days, filter, and vacuum dry at 40°C for 48 h. Perform PXRD, DSC, and TGA characterization to confirm that aripiprazole-myristic acid cocrystal (APZ-C14) is obtained.

[0086] Example 4

[0087] Weigh 2.24 g of aripiprazole and 1.28 g of palmitic acid, mix them, add 10 mL of acetonitrile solution to make a suspension, stir at room temperature for 3 days, filter, and vacuum dry at 40°C for 48 h. Perform PXRD, DSC, and TGA characterization to confirm that aripiprazole-palmitic acid cocrystal (APZ-C16) is obtained.

[0088] Example 5

[0089] Aripiprazole Form III (448 mg) and capric acid (172 mg) were weighed and mixed, 40 mL of acetonitrile was added, and the mixture was dissolved by ultrasonic heating and filtered into a beaker. The solvent was slowly evaporated until crystals precipitated. The product was dried and characterized by PXRD, DSC and TGA to confirm that aripiprazole-capric acid cocrystal (APZ-C10) was obtained.

[0090] Example 6

[0091] Aripiprazole Form III (448 mg) and lauric acid (200 mg) were weighed and mixed, 50 mL of acetonitrile was added, and the mixture was dissolved by ultrasonic heating and filtered into a beaker. The solvent was slowly evaporated until crystals precipitated. The product was dried and characterized by PXRD, DSC and TGA to confirm that aripiprazole-lauric acid cocrystal (APZ-C12) was obtained.

[0092] Example 7

[0093] Aripiprazole form III (448 mg) and myristic acid (228 mg) were weighed and mixed, 50 mL of acetonitrile was added, and the mixture was dissolved by ultrasonic heating and filtered into a beaker. The solvent was slowly evaporated until crystals precipitated. The product was dried and characterized by PXRD, DSC and TGA to confirm that aripiprazole-myristic acid cocrystal (APZ-C14) was obtained.

[0094] Example 8

[0095] Aripiprazole Form III (448 mg) and palmitic acid (256 mg) were weighed and mixed, 50 mL of acetonitrile was added, and the mixture was dissolved by ultrasonic heating and filtered into a beaker. The solvent was slowly evaporated until crystals precipitated. The product was dried and characterized by PXRD, DSC and TGA to confirm that aripiprazole-palmitic acid cocrystal (APZ-C16) was obtained.

[0096] Example 9

[0097] A certain amount of aripiprazole form III (50 mg) and capric acid (19 mg) were weighed, 5 mL of acetone was added to dissolve, and the mixture was slowly added dropwise to the aqueous solution under stirring. The product was filtered and dried, and characterized by PXRD, DSC, and TGA to confirm that aripiprazole-capric acid cocrystal (APZ-C10) was obtained.

[0098] Example 10

[0099] A certain amount of aripiprazole form III (50 mg) and lauric acid (22 mg) were weighed, 5 mL of acetone was added to dissolve, and the mixture was slowly added dropwise to the aqueous solution under stirring. The product was filtered and dried, and characterized by PXRD, DSC, and TGA to confirm that aripiprazole-lauric acid cocrystal (APZ-C12) was obtained.

[0100] Embodiment 11

[0101] A certain amount of aripiprazole form III (50 mg) and myristic acid (25 mg) were weighed, 5 mL of acetone was added to dissolve, and the mixture was slowly added dropwise to the aqueous solution under stirring. The product was filtered and dried, and characterized by PXRD, DSC, and TGA to confirm that aripiprazole-myristic acid cocrystal (APZ-C14) was obtained.

[0102] Example 12

[0103] A certain amount of aripiprazole form III (50 mg) and palmitic acid (29 mg) were weighed, 5 mL of acetone was added to dissolve, and the mixture was slowly added dropwise to the aqueous solution under stirring. The product was filtered and dried, and characterized by PXRD, DSC, and TGA to confirm that aripiprazole-palmitic acid cocrystal (APZ-C16) was obtained.

[0104] Example 13

[0105] A certain amount of aripiprazole crystal form III (448 mg) and capric acid (172 mg) were weighed, mixed thoroughly, heated on a 140°C hot plate to melt, taken out and quenched on an aluminum block, placed at room temperature for 30 minutes, and then heated again at 60°C until the amorphous crystallization was complete. PXRD, DSC, and TGA characterizations were performed to confirm that aripiprazole-capric acid cocrystal (APZ-C10) was obtained.

[0106] Embodiment 14

[0107] A certain amount of aripiprazole crystal form III (448 mg) and lauric acid (200 mg) were weighed, mixed thoroughly, heated on a 140°C hot plate to melt, taken out and quenched on an aluminum block, placed at room temperature for 30 minutes, and then heated again at 60°C until the amorphous crystallization was complete. PXRD, DSC, and TGA characterizations were performed to confirm that aripiprazole-lauric acid cocrystal (APZ-C12) was obtained.

[0108] Embodiment 15

[0109] A certain amount of aripiprazole crystal form III (448 mg) and myristic acid (228 mg) were weighed, mixed thoroughly, heated on a 140°C hot plate to melt, taken out and quenched on an aluminum block, placed at room temperature for 30 minutes, and then heated again at 60°C until the amorphous crystallization was complete. PXRD, DSC, and TGA characterizations were performed to confirm that aripiprazole-myristic acid cocrystal (APZ-C14) was obtained.

[0110] Example 16

[0111] A certain amount of aripiprazole crystal form III (448 mg) and palmitic acid (256 mg) were weighed, mixed thoroughly, heated on a 140°C hot plate to melt, taken out and quenched on an aluminum block, placed at room temperature for 30 minutes, and then heated again at 60°C until the amorphous crystallization was complete. PXRD, DSC, and TGA characterizations were performed to confirm that aripiprazole-palmitic acid cocrystal (APZ-C16) was obtained.

[0112] Embodiment 17

[0113] A certain amount of aripiprazole form III (448 mg) and capric acid (172 mg) were weighed, 40 mL of acetonitrile was added as solvent, heated to 60°C to dissolve, then cooled to 4°C, filtered, and the product was dried. PXRD, DSC, and TGA characterization were performed to confirm that aripiprazole-decanoic acid cocrystal (APZ-C10) was obtained.

[0114] Embodiment 18

[0115] A certain amount of aripiprazole form III (448 mg) and lauric acid (200 mg) were weighed, 50 mL of acetonitrile was added as a solvent, heated to 60°C to dissolve, then cooled to 4°C, filtered, and the product was dried. PXRD, DSC, and TGA characterization were performed to confirm that aripiprazole-lauric acid cocrystal (APZ-C12) was obtained.

[0116] Embodiment 19

[0117] A certain amount of aripiprazole form III (448 mg) and myristic acid (228 mg) were weighed, 50 mL of acetonitrile was added as solvent, the mixture was heated to 60°C to dissolve, then cooled to 4°C, filtered, and the product was dried. PXRD, DSC, and TGA characterization were performed to confirm that aripiprazole-myristic acid cocrystal (APZ-C14) was obtained.

[0118] Embodiment 20

[0119] A certain amount of aripiprazole form III (448 mg) and palmitic acid (256 mg) were weighed, 50 mL of acetonitrile was added as a solvent, the mixture was heated to 60°C to dissolve, then cooled to 4°C, filtered, and the product was dried. PXRD, DSC, and TGA characterization were performed to confirm that aripiprazole-palmitic acid cocrystal (APZ-C16) was obtained.

[0120] Embodiment 21

[0121] 996 mg of aripiprazole form III and 344 mg of capric acid were weighed and mixed evenly, 60 μL of acetonitrile was added to assist grinding, and the mixture was dried and characterized by PXRD, DSC, and TGA to confirm that aripiprazole-capric acid cocrystal (APZ-C10) was obtained.

[0122] Embodiment 22

[0123] 996 mg of aripiprazole form III and 400 mg of lauric acid were weighed and mixed evenly, 60 μL of acetonitrile was added to assist grinding, and the mixture was dried. PXRD, DSC, and TGA characterization were performed to confirm that aripiprazole-lauric acid cocrystal (APZ-C12) was obtained.

[0124] Embodiment 23

[0125] 996 mg of aripiprazole form III and 456 mg of myristic acid were weighed and mixed evenly, 60 μL of acetonitrile was added to assist grinding, and the mixture was dried. PXRD, DSC, and TGA characterization were performed to confirm that aripiprazole-myristic acid cocrystal (APZ-C14) was obtained.

[0126] Embodiment 24

[0127] 996 mg of aripiprazole form III and 512 mg of palmitic acid were weighed and uniformly mixed, 60 μL of acetonitrile was added to assist grinding, and the mixture was dried and characterized by PXRD, DSC, and TGA to confirm that aripiprazole-palmitic acid cocrystal (APZ-C16) was obtained.

[0128] Embodiment 25

[0129] Weigh 10g of aripiprazole API, add 200mL of a mixed solvent of ethanol and water (4:1), reflux at 70°C for 2h, slowly cool to room temperature, filter, vacuum dry at 40°C for 48h, and confirm that aripiprazole monohydrate (APZMH) is obtained by solid-state characterization. Spread aripiprazole monohydrate on a 100°C hot plate and heat for 30min, and confirm that aripiprazole crystal form III (APZF3) is obtained by solid-state characterization.

[0130] Embodiment 26

[0131] Weigh 296.3 mg of aripiprazole-palmitic acid eutectic passed through an 80-mesh sieve, add 3 mL of an aqueous solution containing 30 mg of Tween 20 and 4 g of 1 mm diameter zirconium oxide grinding beads, grind at 800 rpm for 2 h, then add appropriate amounts of sodium chloride, sodium citrate, sodium dihydrogen phosphate and sodium hydrogen phosphate to adjust the osmotic pressure and pH value of the preparation to obtain an aripiprazole-palmitic acid eutectic nanosuspension with a particle size of 516.87±2.87 nm and a PDI of 0.22±0.02.

[0132] Example 27: Drug Cocrystal Structure Characterization

[0133] The single crystal structures of the aripiprazole-fatty acid co-crystals prepared in Examples 5 to 8 were analyzed, and the results showed that all the aripiprazole-fatty acid co-crystals belonged to the triclinic system. Space group, measuring the distance difference Δd between the two carbon-oxygen bonds in the carboxylic acid in different aripiprazole-fatty acid cocrystal structures (C-O) , 0.119 (APZ-C10), 0.121 (APZ-C12), 0.116 (APZ-C14) and 0.120 (APZ-C16), respectively. According to the carboxylic acid rule for distinguishing eutectics from salts (Δd (C-O) Greater than Δd of carboxylate anion (C-O) Less than ), it can be seen that the multi-component single-phase solid prepared by aripiprazole and fatty acid is a cocrystal rather than a salt. The crystallographic parameters of aripiprazole-fatty acid cocrystals with different alkane chain lengths are shown in Table 1. The unit cell volume V, axis length c, and unit cell density ρ show a good monotonic change trend with the change of fatty acid alkane chain length in the drug cocrystal. The asymmetric unit of different aripiprazole-fatty acid cocrystals is shown in Table 1. Figure 1 to Figure 4 .

[0134] By analyzing the crystal structure and interaction force of aripiprazole-fatty acid cocrystals, it was found that the molecular stacking characteristics of aripiprazole-fatty acid cocrystals with different alkane chain lengths are highly consistent ( Figure 1 , Table 2). Taking aripiprazole-decanoic acid cocrystal as an example, the amide groups of two aripiprazole molecules are bonded by NH…O hydrogen bonds (N3-H3…O2, ) self-assemble into a The further extension of the dimer is mainly through the hydroxyl group on the carboxyl end of decanoic acid and the nitrogen atom on the aripiprazole piperazine ring far away from the benzene ring to form OH...N(O3-H3...N2, ) hydrogen bond. In addition, the carbonyl group at the carboxyl end of decanoic acid forms a CH…O(C9-H9…O4, ) hydrogen bond and the CH…O(C3-H3…O3, )Hydrogen bonds are also involved in the construction of aripiprazole-decanoic acid cocrystal.

[0135] Table 1 Crystallographic parameters of aripiprazole-fatty acid cocrystals

[0136]

[0137]

[0138] Table 2 Hydrogen bonding information of aripiprazole-fatty acid cocrystal

[0139]

[0140]

[0141] The solid-state characterization results of aripiprazole-fatty acid cocrystal and aripiprazole Form III are shown in Figure 5 to Figure 7 . Before 100°C, aripiprazole-fatty acid cocrystals and aripiprazole crystal form III (APZF3) did not lose weight significantly with increasing temperature, indicating that all samples existed in a solvent-free form. When the temperature rose to 125°C, aripiprazole-fatty acid cocrystal samples began to lose weight one after another, and the starting temperature corresponding to the weight loss of drug cocrystal samples increased with the increase of the fatty acid alkane chain length in the drug cocrystal.

[0142] Differential scanning calorimetry curves of all aripiprazole-fatty acid cocrystals ( Figure 6 ) all showed sharp melting endothermic peaks, indicating high phase purity. The melting points of aripiprazole-fatty acid eutectics were 75.33±0.52℃(APZ-C10), 80.49±0.37℃(APZ-C12), 85.35±0.29℃(APZ-C14) and 87.05±0.29℃(APZ-C16), respectively. The melting points of all aripiprazole-fatty acid eutectics were between the melting points of saturated fatty acids and aripiprazole form III (139℃). The melting points of aripiprazole-fatty acid eutectics with different alkane chain lengths increased with the increase of fatty acid alkane chain length.

[0143] X-ray powder diffraction of aripiprazole-fatty acid cocrystals Figure 7 As shown. The PXRD patterns of aripiprazole-fatty acid cocrystals with different alkane chain lengths are basically consistent in the diffraction peak positions at 2θ of 16-25°, while the diffraction peaks in the low diffraction angle region shift regularly, such as the diffraction peaks at 2θ of 2.5° and 7.0° shift to the low angle region as the fatty acid alkane chain length in the drug cocrystal increases. This result shows that the internal molecular stacking arrangement of aripiprazole-fatty acid cocrystals has good consistency.

[0144] Example 28: Powder dissolution and solution stability evaluation

[0145] 1. Source of test samples

[0146] Aripiprazole API was purchased from Jiangsu Aikon Biopharmaceutical R&D Co., Ltd., and fatty acids were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; Aripiprazole Form III was purified from aripiprazole API.

[0147] 2. Experimental methods

[0148] Weigh 200 mg of aripiprazole-fatty acid cocrystal powder passed through an 80-mesh sieve into a 50-mL centrifuge tube, add 10 mL of 0.25 wt.% sodium dodecyl sulfate (SDS) aqueous solution, place in a 37°C constant temperature shaker, and shake at 100 rpm for 48 h. Take 1 mL of the supernatant at different time points and add 1 mL of blank medium. Centrifuge the taken liquid at 13,000 rpm for 5 min, dilute and inject into HPLC, and perform Raman characterization on the lower solid.

[0149] 3. Experimental results

[0150] The non-sink dissolution curves of aripiprazole-fatty acid cocrystals with different alkane chain lengths in 0.25 wt.% sodium dodecyl sulfate (SDS) aqueous solution are shown in Figure 2. Figure 8 As shown in the figure, the dissolution curves of APZF3, APZ-C10, and APZ-C12 present a "spring-parachute" model, and the concentration of aripiprazole in the solution shows a trend of first rising and then rapidly falling. In the rising section, APZ-C10 and APZ-C12 dissolve faster than APZF3; the falling section is speculated to be caused by phase transition of APZF3, APZ-C10, and APZ-C12 during the dissolution process, but APZ-C12 still dissolves faster than APZF3. The dissolution curves of APZ-C14 and APZ-C16 present a "spring-helicopter" model, and the concentration of aripiprazole in the solution rises rapidly to a certain level in a short period of time and is maintained during the subsequent dissolution process. Comparing the equilibrium solubility of APZ-C14 and APZ-C16, the aripiprazole-fatty acid eutectic with a shorter alkane chain has better solubility.

[0151] Raman characterization was performed on the residue after 24 hours of dissolution. The results are as follows Fig. 9 Compared with aripiprazole monohydrate (APZMH) at 1320 cm -1 Based on the characteristic Raman peaks at , it is believed that APZF3 and aripiprazole-fatty acid cocrystals with shorter alkane chains (APZ-C10 and APZ-C12) are transformed into aripiprazole monohydrate during the dissolution process, while the aripiprazole-fatty acid cocrystals with longer alkane chains (APZ-C14 and APZ-C16) still exist as drug cocrystals after 24 hours of dissolution.

[0152] Example 29: Evaluation of intrinsic dissolution rate

[0153] 1. Source of test samples

[0154] Aripiprazole API was purchased from Jiangsu Aikon Biopharmaceutical R&D Co., Ltd., and fatty acids were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; Aripiprazole Form III was purified from aripiprazole API.

[0155] 2. Experimental methods

[0156] 50 mg of aripiprazole crystal form III and aripiprazole-fatty acid cocrystal powders that had passed through an 80-mesh sieve were weighed separately and placed in an intrinsic dissolution mold with a diameter of 4 mm, and pressed at a pressure of 200 kg for 1 minute. After the pressing was completed, the mold was removed to expose one side of the tablet to 550 mL of dissolution medium (0.25 wt.% sodium dodecyl sulfate aqueous solution (SDS)), and the tablet was dissolved at 37° C. and 50 rpm. 4 mL of sample solution was sampled at different time points (2, 4, 6, 8, 10, 12, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 min) and supplemented with an equal amount of constant-temperature blank medium. The sample solution was centrifuged at 13,000 rpm for 5 minutes, and the supernatant was taken for HPLC injection.

[0157] HPLC experimental conditions:

[0158] Instrument: Shimadzu LC-20AT high performance liquid chromatograph;

[0159] Chromatographic UV detector model: Shimadzu SPD-20A;

[0160] Chromatographic quaternary pump model: Shimadzu LC-20AT;

[0161] Chromatographic column: Agilent Zorbax SB C-18 (4.6×250 mm, 5 μm);

[0162] Mobile phase: acetonitrile:0.1% formic acid-0.1% ammonia aqueous solution (v / v, 60:40);

[0163] Column temperature: 40°C;

[0164] Flow rate: 1 mL / min;

[0165] Injection volume: 50 μL;

[0166] Detection wavelength: 254nm.

[0167] 3. Experimental results

[0168] The intrinsic dissolution results of aripiprazole-fatty acid cocrystals are as follows Fig.10As shown. Overall, the dissolution of aripiprazole-fatty acid cocrystal and aripiprazole crystal form III was carried out at a constant rate, and the concentration of the drug in the dissolution medium showed a good linear relationship with time. The extraction slope was used to calculate the intrinsic dissolution rate of aripiprazole-fatty acid cocrystals with different alkane chain lengths ( Fig.11 and Table 3), and some groups were linearly fitted in a shorter time. The results showed that the intrinsic dissolution rates of all aripiprazole-fatty acid cocrystals were faster than those of aripiprazole form III (APZF3) group, and the intrinsic dissolution rates of aripiprazole-fatty acid cocrystals with different alkane chain lengths slowed down with the increase of chain length, in the order of APZ-C10>APZ-C12>APZ-C14>APZ-C16.

[0169] Table 3 Intrinsic dissolution rates of aripiprazole form III and aripiprazole-fatty acid cocrystal in 0.25wt.% SDS aqueous solution

[0170]

[0171] Raman characterization was performed on the side of all aripiprazole-fatty acid cocrystals and aripiprazole form III (APZF3) in contact with the dissolution medium after the intrinsic dissolution test. The results are as follows: Fig.12 As shown in the data, aripiprazole form III (APZF3), aripiprazole-decanoic acid cocrystal (APZ-C10), and aripiprazole-lauric acid cocrystal (APZ-C12) underwent crystal transformation during the intrinsic dissolution experiment, while the remaining aripiprazole-fatty acid cocrystals remained stable after dissolution. This result is consistent with the powder dissolution result, that is, the aripiprazole-fatty acid cocrystal with a longer alkane chain has better solution stability.

[0172] Example 30: Solid-state stability evaluation

[0173] 1. Experimental methods

[0174] An appropriate amount of aripiprazole-fatty acid cocrystal powder passed through an 80-mesh sieve was weighed and placed in an open incubator at 40°C / 75%RH. The powder was taken out at different time intervals (0 month, 1 month, 3 months, and 6 months) and characterized by X-ray powder diffraction. The test conditions were the same as the detection method in Example 29.

[0175] 2. Experimental results

[0176] The solid-state stability characterization results of aripiprazole-fatty acid cocrystals with different alkane chain lengths at 40°C / 75%RH are shown in Figure 2. Fig.13By comparing the PXRD patterns of the aripiprazole-fatty acid cocrystals before placement (indicated by 0 in the figure), the aripiprazole-fatty acid cocrystals with different alkane chain lengths did not undergo crystal transformation under accelerated experimental conditions for up to 6 months, nor did they show any correlation with the alkane chain length. This indicates that the aripiprazole-fatty acid cocrystals prepared by the present invention have good physical stability and are suitable for long-term storage under solid conditions.

[0177] Example 31: Pharmacokinetic Evaluation

[0178] 1. Experimental methods

[0179] Sixteen male SPF SD rats (250-275 g) were randomly divided into four groups (n=4), and the ears were numbered, and they were recorded as Group A (Aripiprazole Crystal Form III, APZF3), Group B (Aripiprazole-lauric acid cocrystal, APZ-C12), Group C (Aripiprazole-myristic acid cocrystal, APZ-C14), and Group D (Aripiprazole-palmitic acid cocrystal, APZ-C16). They were fasted for 12 hours before the experiment and had free access to water. The dosage was 3 mg / kg (in terms of Aripiprazole), and the route of administration was oral gavage. At different time points (5min, 15min, 30min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, 10h, 24h), 0.4mL of blood was collected from the rat orbit and placed in a 2mL sodium heparin centrifuge tube. The blood was centrifuged at 10000rpm for 10min, and the upper plasma was stored in a -80℃ refrigerator until LC-MS / MS detection. The chromatographic column used for LC-MS / MS detection was Water C18 column (150×4.6mm, 5μm), mobile phase: 0.05% ammonia water-0.05% formic acid water: acetonitrile (v / v, 15:85), injection volume: 5μl, flow rate: 0.5ml / min, column temperature: 38℃.

[0180] 2. Experimental results

[0181] After oral administration of aripiprazole crystal form III (APZF3) and aripiprazole-fatty acid cocrystal to rats, the in vivo aripiprazole blood concentration versus time curve and the calculated pharmacokinetic parameters are shown in Figure 2. Fig.14 As shown in Table 4. Compared with the aripiprazole crystal form III (APZF3) group, the aripiprazole-fatty acid cocrystal had a faster release rate within 90 min and a higher peak blood concentration (C max ). Among them, the C max (153.97±74.59ng / mL) is aripiprazole crystal form III (APZF3) (C max: 49.87±10.13ng / mL), nearly 3 times that of aripiprazole-lauric acid cocrystal (APZ-C12) and aripiprazole-palmitic acid cocrystal (APZ-C16). max (APZ-C12: 63.11 ± 14.93 ng / mL, APZ-C16: 97.00 ± 18.33) are respectively aripiprazole form III (APZF3) (C max :49.87±10.13ng / mL), which is 1.3 and 1.9 times of that in the control group.

[0182] The area under the plasma concentration-time curve was calculated. When the dosage was the same, the bioavailability (AUC) of aripiprazole-myristic acid cocrystal (APZ-C14) with the best powder dissolution properties in vitro was higher than that of aripiprazole form III (APZF3). 0-24h :50811.80±8214.94ng / mL*min) was significantly improved, which was the aripiprazole crystal form III (APZF3) group (AUC 0-24h :38697.01±1181.69ng / mL*min), 1.3 times.

[0183] Table 4 Pharmacokinetic parameters of aripiprazole-fatty acid cocrystal and aripiprazole form III in rats

[0184]

[0185] In summary, the present invention adopts the drug co-crystal strategy without changing the drug efficacy, and uses fatty acids with good biosafety as ligands to prepare a new series of aripiprazole-fatty acid co-crystals. Through crystal structure analysis, the series of drug co-crystals designed by the present invention have a clear co-crystal crystal structure. Compared with the commercially available aripiprazole crystal form III, the physicochemical properties and drug release behavior of this series of drug co-crystals are significantly improved, including solubility, dissolution rate, stability, bioavailability, etc., and the properties of the drug co-crystals show a good monotonic change trend with the alkane chain length. By selecting fatty acids with suitable alkane chain lengths as ligands, drugs with expected properties can be designed. In addition, this series of drug co-crystals has good stability, and the preparation method is convenient and economical, which is conducive to industrial production.

Claims

1. A quinolinone drug cocrystal, characterized in that: It is formed by aripiprazole and a saturated fatty acid ligand with 10 to 16 carbon atoms; in the cocrystal structure, the amide groups of two aripiprazole molecules are connected by NH … O hydrogen bond self-assembly The homodimer is a homodimer formed by the OH group on the carboxyl end of the saturated fatty acid molecule and the nitrogen atom on the piperazine ring in the aripiprazole molecule far from the benzene ring. … N hydrogen bond extension.

2. The quinolinone drug co-crystal according to claim 1, characterized in that: The saturated fatty acid is selected from capric acid, lauric acid, myristic acid and palmitic acid, wherein the molar ratio of aripiprazole to the saturated fatty acid is 1-2:1-2.

3. An aripiprazole-decanoic acid cocrystal, characterized in that: It is a triclinic system. Space group; unit cell parameters are α=81.285(4)°, β=82.440(5)°, γ=74.182(4)°.

4. The aripiprazole-decanoic acid cocrystal according to claim 3, characterized in that: Expressed as a diffraction angle of 2θ±0.2°, it has characteristic diffraction peaks at 4.16°, 8.32°, 16.72°, 19.74°, and 22.24°.

5. The aripiprazole-decanoic acid cocrystal according to claim 3, characterized in that: It has a characteristic melting peak at 75.3±0.5℃.

6. An aripiprazole-lauric acid cocrystal, characterized in that: It is a triclinic system. Space group; unit cell parameters are α=91.364(2)°, β=98.872(2)°, γ=106.0730(10)°.

7. The aripiprazole-lauric acid cocrystal according to claim 6, characterized in that: Expressed as a diffraction angle of 2θ±0.2°, it has characteristic diffraction peaks at 3.90°, 7.82°, 9.64°, 15.7°, 18.14°, 20.76°, 21.54°, 23.62°, and 24.44°.

8. The aripiprazole-lauric acid cocrystal according to claim 6, characterized in that: It has a characteristic melting peak at 80.5±0.4℃.

9. An aripiprazole-myristic acid cocrystal, characterized in that: It is a triclinic system. Space group; unit cell parameters are α=95.2340(10)°, β=93.7410(10)°, γ=106.2470(10)°.

10. The aripiprazole-myristic acid cocrystal according to claim 9, characterized in that: Expressed as a diffraction angle of 2θ±0.2°, it has characteristic diffraction peaks at 3.72°, 7.43°, 14.90°, 17.18°, 18.22°, 18.67°, 23.10°, 26.52°, and 27.82°.

11. The aripiprazole-myristic acid cocrystal according to claim 9, characterized in that: There is a characteristic melting peak at 85.3±0.3℃.

12. An aripiprazole-palmitic acid cocrystal, characterized in that: It is a triclinic system. Space group; unit cell parameters are α=70.367(2)°, β=80.901(2)°, γ=78.615(2)°.

13. The aripiprazole-palmitic acid cocrystal according to claim 12, characterized in that: Expressed as a diffraction angle of 2θ±0.2°, it has characteristic diffraction peaks at 3.56°, 7.02°, 14.10°, 17.18°, 17.70°, 18.28°, 21.14°, 21.58°, 21.78°, 24.20°, and 24.92°.

14. The aripiprazole-palmitic acid cocrystal according to claim 12, characterized in that: There is a characteristic melting peak at 87.1±0.3℃.

15. A method for preparing a co-crystal according to any one of claims 1 to 14, characterized in that: Choose from any of the following methods: Method 1: preparing a suspension of aripiprazole and fatty acid, stirring, and removing the solvent to obtain the co-crystal; Method 2: dissolving aripiprazole and fatty acid, filtering, removing the solvent from the filtrate, and crystallizing to obtain the co-crystal; Method 3: dissolving aripiprazole and fatty acid, then mixing with anti-solvent, and removing the solvent to obtain the co-crystal; Method 4: heating aripiprazole and fatty acid until they are melted and cooling them to obtain the co-crystal; Method 5: dissolving aripiprazole and fatty acid, cooling, and removing the solvent to obtain the co-crystal; Method 6: Aripiprazole and fatty acid are mixed and ground to obtain the co-crystal.

16. A pharmaceutical composition, characterized in that The co-crystal according to any one of claims 1 to 14 is used as an active ingredient.

17. Use of the cocrystal according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 16 in the preparation of a medicament for preventing and / or treating central nervous system diseases or disorders related to the central nervous system.

18. The use according to claim 17, characterized in that The drug is a drug for preventing and / or treating schizophrenia, mania, bipolar disorder, mixed episodes of bipolar disorder, depression, autism, autism-related hypersensitivity, Tourette syndrome, Alzheimer's disease, dementia, epilepsy, anxiety, tic disorder, irritability associated with childhood autism, tourette syndrome, alcoholism, trichotillomania, dermatitis, autism spectrum disorder, tumor, emergence delirium, attention deficit disorder with hyperactivity, metabolic syndrome, postpartum depression, developmental disorder, opioid dependence, cocaine addiction, Asperger's syndrome, HIV infection, fragile X chromosome syndrome, post-traumatic stress disorder, and weight changes caused by mental disorders.

Citation Information

Patent Citations

  • Aripiprazole crystal form suitable for pharmaceutical use, preparation method and pharmaceutical compositions

    CN101333189A

  • Aripiprazole new crystal form and preparation method thereof

    CN105924393A

  • Aripiprazole pharmaceutical co-crystal and preparation method thereof

    CN113105389A

  • Aripiprazole eutectic crystal and pharmaceutical composition and application thereof

    CN117903050A

  • Aripiprazole crystal form

    CN1676517A